Hepatology

Gastrointestinal Cancers

Questions discussed in this category

Which patients, if any, do you revert back to ultrasound screening for HCC after prior diagnosis/definitive treatment of HCC?

What imaging modality do you prefer after 5 years of a patient remaining NED?

1 Answer available

How are you treating MSI-H CRC in a liver transplant recipient on tacrolimus & sirolimus?

History of OLT (3 years ago), no response to pembro mono tx after 2 mo. Too immunosuppressed?

2 Answers available

What is your approach to liver transplantation candidacy in those with decompensated cirrhosis who have been treated for a solid-organ malignancy, such as oral SCC?

Is there a minimum time of waiting that is necessary between the completion of cancer treatment and liver transplantation?

1 Answer available

Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?

Patient with extrahepatic cholangiocarcinoma s/p Whipple in 2021 with negative margins and no positive nodes followed by adjuvant chemo with subsequen...

2 Answers available

When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?

Data are scattered, with some starting concurrent and some starting after SBRT to optimize the priming of the immune system with RT.

1 Answer available

Would you ever consider using durvalumab/tremelimumab in second line after progression on atezolizumab and bevacizumab in advanced HCC?

3 Answers available

How do you manage oxaliplatin-induced splenomegaly?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Mar 19

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.

Hepatology (Baltimore, Md.), 2023 May 22

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology, 2025 Jan 15

Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.

Investigational new drugs, 2024 Aug 30

Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020 Oct 23

Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.

Radiother Oncol, 2017 May

Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-05-20

Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.

Frontiers in oncology, 2025 Oct 29

Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2024 Apr 18

Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.

BMC medicine, 2025 Sep 02

Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.

European journal of cancer (Oxford, England : 1990), 2021 Mar 12

Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.

JAMA oncology, 2025 Oct 01

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis.

Nature communications, 2019 Oct 17

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Hepatology

Gastrointestinal Cancers

Questions discussed in this category

Papers discussed in this category

Related Topics in Hepatology